QT Imaging (QTI) Q2 2026: 103% Revenue Growth Anchored by Strategic Commercial Expansion
QT Imaging doubled revenue year-over-year driven by increased scanner shipments and expanded U.S. commercial infrastructure. The company reinforced its regulatory footprint internationally and advanced clinical evidence to support broader adoption. Continued operational investments and a strengthened balance sheet position QTI for scalable growth into 2027.
Summary
- Commercial Model Expansion: Direct U.S. sales team growth complements established distribution channels to accelerate adoption.
- Regulatory and Clinical Momentum: New clearances in Israel and Saudi Arabia bolster global market access and clinical study initiatives.
- Operational Scaling: Expanded manufacturing footprint and capital raise provide foundation for sustainable volume growth.
Business Overview
QT Imaging is a medical device company specializing in Breast Acoustic CT, a radiation-free, compression-free imaging platform designed to improve breast health management. The company generates revenue primarily through the sale of its Breast Acoustic CT scanners, supported by software and cloud-based quantitative imaging solutions. Its commercial operations are segmented between the United States and international markets, leveraging a combination of direct sales teams and distribution partnerships.
Performance Analysis
QT Imaging reported second quarter revenue of $7.4 million, representing a 103% increase year-over-year, driven by the shipment of 15 scanners compared to eight in the prior year quarter. For the first half of 2026, revenue totaled $14.0 million on 28 scanners shipped, doubling the prior year’s volume and revenue. This growth reflects the company’s successful scaling of commercial activities, particularly in the U.S. where direct sales efforts are gaining traction alongside existing distribution partnerships.
Gross margin contracted to 41% from 50% year-over-year, aligning with expectations for U.S. sales where higher costs of inventory impacted profitability. Operating expenses rose to $4.9 million, reflecting investments in personnel, professional services, and marketing to support commercial expansion. The operating loss widened to $1.9 million, while net loss increased to $11.1 million due largely to a non-cash $8.3 million charge related to debt restructuring. Cash and restricted cash improved to $14.2 million as of early August, supported by a $10 million public offering and accounts receivable collections.
- Revenue Growth Leverage: Scanner shipment volume doubled, underscoring successful commercial execution.
- Margin Pressure from U.S. Sales Mix: Higher weighted average cost of inventory and expanded sales infrastructure compressed gross margin.
- Cash Position Strengthened: Capital raise and loan amendment provide financial flexibility amid growth investments.
Overall, QTI’s financial performance illustrates a transition phase where revenue scaling is balanced against elevated operating and financing expenses as the company builds a foundation for sustainable growth.
Executive Commentary
"Our second quarter results demonstrate continued execution and the growing commercial momentum of QT Imaging. Revenue more than doubled year-over-year to $7.4 million, and we shipped fifteen Breast Acoustic CT scanners during the quarter, compared with eight in the prior-year period."
Dr. Raluca Dinu, Chief Executive Officer
"The gross margin for the second quarter of 2026 was in line with our projections for sales in the USA. The increase in operating expenses reflects investments in employee compensation, professional services, and marketing to support our expanding commercial infrastructure."
Jay Jennings, Chief Financial Officer
Strategic Positioning
1. Dual Commercial Model Enhances Market Penetration
QT Imaging is advancing a hybrid go-to-market approach, combining exclusive distribution partnerships—such as with NXE Imaging in the U.S.—with an expanding direct sales force. The appointment of regional sales VPs for East and West coasts strengthens direct engagement with breast imaging centers, hospitals, and enterprise health systems. This model is designed to accelerate adoption, deepen customer relationships, and support scalable revenue and margin expansion.
2. International Regulatory Expansion Enables Market Access
Clearances from the Saudi Food and Drug Authority and Israel’s Ministry of Health, alongside existing UAE authorization, broaden the company’s addressable markets in the Middle East. QTI’s partner-led distribution model in these regions offers capital efficiency while allowing penetration into diverse healthcare systems. The planned clinical study at Rambam Health Care Campus in Israel targeting high-risk women underscores a commitment to build clinical evidence supporting adoption.
3. Clinical Evidence Builds Quantitative Imaging Platform
QTI is advancing multiple clinical studies, including a new 100-patient Mayo Clinic trial comparing Breast Acoustic CT to MRI, aiming to demonstrate diagnostic equivalency and reduce unnecessary biopsies. Repeatability studies showing less than 1% variability in Speed of Sound measurements reinforce the platform’s potential for objective, reproducible quantitative biomarkers. These efforts position the company to leverage its CPT Category 3 reimbursement code for data collection and future coverage expansion.
4. Manufacturing Scale and Operational Efficiency
The relocation to a 22,000-square-foot facility in Petaluma, California, more than doubling operational space while reducing lease costs by approximately 55%, reflects a strategic investment to support volume growth and improve manufacturing efficiency. The successful completion of a routine FDA inspection with zero observations further validates the company’s quality management system and readiness to scale.
5. Strengthened Financial Flexibility Supports Growth Initiatives
A $10 million public offering and amendment of the senior secured term loan, extending maturity by two years and adjusting interest terms, enhance liquidity and provide runway to execute commercial and clinical strategies. The company maintains its 2026 revenue guidance of approximately $39 million, reflecting confidence in shipment commitments and direct sales contributions.
Key Considerations
QT Imaging’s second quarter highlights a pivotal stage in its evolution from early commercial validation to scalable growth. Key considerations include:
- Commercial Execution: The balance between direct sales investments and distributor partnerships will be critical to accelerate adoption and manage costs.
- Clinical Validation: Outcomes from ongoing studies will be instrumental in driving physician adoption and payer coverage decisions.
- International Market Development: Regulatory progress in the Middle East and potential expansion into Bahrain and Qatar offer growth avenues but carry geopolitical and market execution risks.
- Margin Dynamics: Managing cost of goods sold and operating expenses amid scaling will be essential to improve profitability.
- Capital Management: The company’s strengthened cash position provides flexibility but requires disciplined burn management to extend runway.
Risks
QT Imaging faces risks typical of emerging medical device companies, including execution risk in commercial scaling, regulatory approvals in new markets, and the need to demonstrate clear clinical and economic benefits to drive adoption. Geopolitical tensions in the Middle East could disrupt international sales efforts. Additionally, the company’s net losses and non-cash charges highlight financial challenges that require careful capital allocation and operational discipline.
Forward Outlook
For the third quarter of 2026, QT Imaging expects to ship approximately 15 scanners in the U.S., with an anticipated increase in placements through Q3 and Q4. Operating expenses are expected to rise moderately due to sales team expansion and clinical study costs. For full-year 2026, the company reaffirms revenue guidance of approximately $39 million, reflecting distributor minimum order quantities and direct sales contributions. Management emphasizes priorities to accelerate adoption, strengthen clinical evidence, expand global market access, and advance the quantitative imaging platform with operational discipline.
Takeaways
QT Imaging’s Q2 2026 results underscore a company in transition, moving from nascent commercial activity to building a scalable, multi-channel sales engine supported by clinical validation and regulatory expansion. The company’s investments in direct sales leadership and manufacturing capacity signal a commitment to long-term growth despite near-term margin pressure and elevated losses. Progress in clinical studies and reimbursement coding lays the groundwork for broader adoption and potential coverage gains. Investors should monitor execution on commercial expansion, clinical data milestones, and international regulatory developments as key indicators of sustained momentum into 2027.
- Commercial Model Evolution: The dual approach combining direct sales and distribution is designed to deepen customer engagement and drive volume growth.
- Clinical and Regulatory Advances: New market clearances and ongoing studies enhance the platform’s credibility and market access.
- Operational and Financial Foundation: Expanded manufacturing footprint and capital raise provide runway, but disciplined cost management remains critical.
Conclusion
QT Imaging’s strong revenue growth and strategic investments in commercial capabilities, clinical evidence, and regulatory expansion position it well for the next growth phase. While near-term losses and margin pressures persist, the company is building a comprehensive platform and infrastructure to support broader adoption of its innovative breast imaging technology.
Industry Read-Through
QT Imaging’s progress highlights the increasing importance of quantitative, radiation-free imaging solutions in breast health management. The successful integration of advanced hardware, software, and cloud infrastructure with emerging AI applications reflects broader industry trends toward personalized, data-driven diagnostics. The company’s hybrid commercial model and international regulatory push illustrate strategies that other medtech firms may adopt to accelerate adoption in fragmented healthcare markets. Additionally, the critical role of clinical validation and reimbursement coding underscores ongoing challenges and opportunities in commercializing innovative imaging modalities.